Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
New Cancer Therapy: A Combination of RNA Interference and Gene Therapy
EF 2022-23
Résumé
Many people are suffering from cancer, which comes in different types and stages. Cancer is an abnormal cell growth and division that is usually hard to treat, and the current therapies have many adverse effects. Therefore, gene therapies for cancer have been heavily studied, but a lot of challenges prevent their application. Such challenges are targeting cancer cells only and avoiding the immune response. Another challenge is that the developed gene therapies tend to be very specific to the tumor type or location, and hence very expensive. Also, the public fear that the viral genome used in gene therapy would integrate into the host genome or would pass to the offspring is delaying the approval of such therapies. I propose a new cancer therapy that would target cancer cells only, would have lower adverse effects, and would be more general among patients. This therapy will be a combination of a gene therapy and an RNA interference (RNAi) therapy using a viral non-integrating vector. It will consist of an adeno-associated virus vector that carries small interfering RNA (siRNA) to turn off the expression specific genes. The vector’s genome will code for a protein that promotes cell death. This research project mainly consists of five phases. The first is to find unique biomarkers on cancer cells membranes. The second is to engineer the viral vector and its components. Third, experiments on cancer cells cultures will be implemented. Fourth, mice cancer models will be used to test the safety and the efficacy of the therapy on mammals. After getting an approval, clinical trials on cancer patients will be implemented in the fifth phase.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486535
Name
Al Mudarris Tasneem
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
New Cancer Therapy: A Combination of RNA Interference and Gene Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adeno-Associated Virus; Cancer; Cancer Membrane Biomarkers; Caspase 3 Protein; Ethical Concerns; Gene Therapy; Membrane Immunoglobulins; Rna Interference Therapy; Silencing Oncogenes
Abstract
Many people are suffering from cancer, which comes in different types and stages. Cancer is an abnormal cell growth and division that is usually hard to treat, and the current therapies have many adverse effects. Therefore, gene therapies for cancer have been heavily studied, but a lot of challenges prevent their application. Such challenges are targeting cancer cells only and avoiding the immune response. Another challenge is that the developed gene therapies tend to be very specific to the tumor type or location, and hence very expensive. Also, the public fear that the viral genome used in gene therapy would integrate into the host genome or would pass to the offspring is delaying the approval of such therapies. I propose a new cancer therapy that would target cancer cells only, would have lower adverse effects, and would be more general among patients. This therapy will be a combination of a gene therapy and an RNA interference (RNAi) therapy using a viral non-integrating vector. It will consist of an adeno-associated virus vector that carries small interfering RNA (siRNA) to turn off the expression specific genes. The vector’s genome will code for a protein that promotes cell death. This research project mainly consists of five phases. The first is to find unique biomarkers on cancer cells membranes. The second is to engineer the viral vector and its components. Third, experiments on cancer cells cultures will be implemented. Fourth, mice cancer models will be used to test the safety and the efficacy of the therapy on mammals. After getting an approval, clinical trials on cancer patients will be implemented in the fifth phase.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Al Mudarris, Tasneem
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~